Crescita Therapeutics Inc.
CRRTF
$0.31
-$0.04-10.71%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.59% | 50.79% | -33.49% | 41.97% | 16.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.59% | 50.79% | -33.49% | 41.97% | 16.54% |
| Cost of Revenue | 54.47% | 28.52% | -34.95% | 128.07% | 4.30% |
| Gross Profit | 43.73% | 69.26% | -31.93% | -4.88% | 29.04% |
| SG&A Expenses | -7.46% | -3.35% | -15.57% | -1.34% | 11.26% |
| Depreciation & Amortization | 21.85% | 14.81% | -13.87% | -6.42% | -18.61% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.42% | 8.88% | -24.56% | 41.48% | 6.18% |
| Operating Income | 86.31% | 155.23% | -36.48% | -21.18% | 16.54% |
| Income Before Tax | 171.97% | 185.24% | -39.87% | -464.35% | 20.53% |
| Income Tax Expenses | -- | -- | -- | -106.91% | -- |
| Earnings from Continuing Operations | 171.97% | 185.24% | -39.87% | -4.90% | 20.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 171.97% | 185.24% | -39.87% | -4.90% | 20.53% |
| EBIT | 86.31% | 155.23% | -36.48% | -21.18% | 16.54% |
| EBITDA | 125.57% | 225.09% | -92.52% | -43.23% | 15.76% |
| EPS Basic | 173.60% | 187.64% | -43.88% | -10.91% | 15.99% |
| Normalized Basic EPS | 201.22% | 187.16% | -43.92% | -331.25% | 16.04% |
| EPS Diluted | 173.60% | 179.18% | -43.88% | 12.86% | 15.99% |
| Normalized Diluted EPS | 201.22% | 186.70% | -43.92% | -331.25% | 16.04% |
| Average Basic Shares Outstanding | -2.26% | -2.62% | -2.88% | -4.33% | -5.38% |
| Average Diluted Shares Outstanding | -2.20% | -2.09% | -2.88% | -4.33% | -5.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |